Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) is now available.
CARsgen Therapeutics Holdings Ltd. has announced a board meeting scheduled for August 14, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is a critical step for the company as it evaluates its financial performance and strategizes for future growth, which may influence its market position and stakeholder interests.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative CAR-T cell therapies for the treatment of cancer. The company is dedicated to advancing its pipeline of products to address unmet medical needs in oncology.
Average Trading Volume: 3,083,616
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.28B
See more insights into 2171 stock on TipRanks’ Stock Analysis page.